Glucagon: A Comprehensive Analysis of its Physiology, Formulation Challenges, and Emerging Therapeutic Modalities

Many thanks to our sponsor Esdebe who helped us prepare this research report.

Abstract

Glucagon, a 29-amino acid peptide hormone primarily secreted by the alpha cells of the pancreatic islets of Langerhans, stands as a critical counter-regulatory hormone to insulin, playing an indispensable role in maintaining glucose homeostasis. Its fundamental physiological function involves elevating blood glucose concentrations, principally through hepatic glycogenolysis and gluconeogenesis, particularly in response to hypoglycemic states or prolonged fasting. While its life-saving therapeutic application in managing severe hypoglycemia in individuals with diabetes has been long established, the widespread utility of glucagon has historically been significantly constrained by its inherent physicochemical instability in aqueous solutions. This instability necessitates its prior reconstitution from lyophilized (freeze-dried) powder formulations, a process often deemed cumbersome and time-consuming, particularly in emergency scenarios.

Recent decades have witnessed remarkable advancements in pharmaceutical material science and formulation technology, leading to the development of innovative, more stable glucagon formulations. These breakthroughs encompass ready-to-use nonaqueous solutions, novel lyophilized powder compositions incorporating advanced excipients, and user-friendly nasal spray delivery systems. Such innovations have not only substantially improved patient compliance and ease of administration but have also considerably broadened glucagon’s clinical utility beyond acute hypoglycemia management, extending its potential into chronic metabolic disease management, including obesity and certain forms of diabetes, and as an integral component of advanced artificial pancreas systems.

This comprehensive report delves deeply into the multifaceted aspects of glucagon, commencing with an elaborate exposition of its intricate physiological roles and the molecular mechanisms underpinning its actions. It then traverses the historical trajectory of glucagon’s development as a therapeutic agent, meticulously examining the formidable challenges encountered in its formulation stability and shelf-life, driven by its susceptibility to both physical aggregation (fibrillation) and chemical degradation. A significant portion of this analysis is dedicated to a detailed exploration of the pioneering material science innovations that have facilitated the emergence of contemporary delivery mechanisms, highlighting the specific excipients, solvent systems, and device engineering principles employed. Finally, the report concludes by exploring the burgeoning potential applications of glucagon and its analogues, offering insights into future directions for this pivotal hormone in metabolic medicine.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

1. Introduction

Glucagon, a polypeptide hormone comprising 29 amino acid residues, represents a cornerstone in the complex regulatory network of human metabolism. Synthesized and secreted predominantly by the alpha cells situated within the pancreatic islets of Langerhans, its primary function is to counteract the actions of insulin by elevating circulating blood glucose levels. This counter-regulatory action is vital for preventing life-threatening hypoglycemia, especially during periods of insufficient caloric intake, intense physical exertion, or pharmacological over-insulinization. The precise amino acid sequence of human glucagon is His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr [Reference 5].

The seminal discovery of glucagon dates back to 1923, shortly after the identification of insulin. C.P. Kimball and John R. Murlin, working at the University of Rochester, isolated a substance from pancreatic extracts that caused a rapid, albeit transient, increase in blood glucose levels, a phenomenon distinct from insulin’s hypoglycemic effect. They coined the term ‘glucagon’, derived from ‘glucose’ and ‘agon’ (from the Greek ‘agonistes’, meaning ‘struggler’ or ‘contender’), signifying its role as a glucose mobilizer [Reference 5]. This initial finding laid the groundwork for understanding the dual hormonal control of glucose homeostasis. Despite its physiological profundity and early recognition of its therapeutic potential, particularly for severe hypoglycemia, the clinical translation and widespread accessibility of glucagon were significantly hampered for decades by its inherent instability. When dissolved in aqueous solutions, glucagon molecules tend to self-associate and form insoluble amyloid-like fibrils, leading to a rapid loss of biological activity and a severely limited shelf-life. This critical challenge has been a major driving force behind extensive research and development efforts in pharmaceutical formulation science, ultimately leading to the innovative, more user-friendly formulations available today.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

2. Physiological Role of Glucagon in Glucose Homeostasis

Glucagon is an exquisitely orchestrated component of the body’s glucose regulatory system, acting as a crucial alarm signal during states of metabolic stress, particularly when blood glucose levels fall or threaten to fall below a physiological set point. Its actions are predominantly directed towards maintaining normoglycemia by mobilizing stored glucose and synthesizing new glucose. The intricate process involves synthesis, secretion, receptor binding, and a cascade of intracellular signaling events that culminate in profound metabolic alterations.

2.1. Synthesis and Secretion

Glucagon is synthesized as part of a larger precursor molecule called proglucagon within the pancreatic alpha cells. Proglucagon undergoes tissue-specific post-translational processing by prohormone convertase 2 (PC2) in the alpha cells, yielding mature glucagon, glicentin-related pancreatic polypeptide (GRPP), and major proglucagon fragment (MPGF). In contrast, the same proglucagon molecule is processed differently in the intestinal L-cells by prohormone convertase 1/3 (PC1/3) to produce glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2), and oxyntomodulin, highlighting a fascinating example of differential gene expression and processing [Reference 6].

The secretion of glucagon from alpha cells is tightly regulated by a complex interplay of nutrient, hormonal, and neural signals. The most potent physiological stimulus for glucagon release is hypoglycemia. Conversely, hyperglycemia, via insulin and somatostatin released from neighboring beta and delta cells respectively, exerts an inhibitory paracrine effect on glucagon secretion. Amino acids, particularly arginine and alanine, are also potent stimulators of glucagon release, which is crucial after a protein-rich meal, helping to prevent post-prandial hypoglycemia that might otherwise occur due to insulin’s action on glucose uptake [Reference 10]. Other modulators include incretin hormones (GLP-1 inhibits glucagon, GIP has a more complex effect), sympathetic and parasympathetic nervous system activity, and various circulating metabolites.

2.2. Mechanism of Action

Upon secretion, glucagon travels through the bloodstream and exerts its primary metabolic effects by binding to the glucagon receptor (GCGR). The GCGR is a G protein-coupled receptor (GPCR) predominantly expressed on the surface of hepatocytes (liver cells), but also found in other tissues such as the kidney, adipose tissue, heart, and brain, albeit to a lesser extent [Reference 6].

Binding of glucagon to its receptor initiates a cascade of intracellular signaling events. The GCGR is primarily coupled to the stimulatory G protein (Gs). Upon ligand binding, the activated GCGR induces a conformational change in Gs, leading to the dissociation of its alpha subunit (Gsα) from the beta-gamma dimer. Gsα then activates adenylate cyclase, an enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP). Elevated intracellular cAMP levels serve as a crucial second messenger, activating protein kinase A (PKA), also known as cAMP-dependent protein kinase [Reference 5].

PKA, a serine/threonine kinase, then phosphorylates a variety of target proteins and enzymes, leading to profound changes in cellular metabolism. This phosphorylation can either activate or inhibit key enzymes involved in glucose production and utilization, thereby orchestrating the rapid release of glucose into the bloodstream.

2.3. Target Organs and Metabolic Effects

2.3.1. Liver (Hepatic Effects)

The liver is the principal target organ for glucagon’s actions, where it orchestrates two major processes to elevate blood glucose:

• Glycogenolysis: Glucagon rapidly stimulates the breakdown of glycogen stores in the liver. PKA phosphorylates and activates glycogen phosphorylase kinase (GPK), which in turn phosphorylates and activates glycogen phosphorylase (GP), the rate-limiting enzyme in glycogenolysis. Simultaneously, PKA phosphorylates and inactivates glycogen synthase, preventing glucose from being re-converted into glycogen. This dual action ensures a rapid and efficient release of glucose from hepatic glycogen stores [Reference 5].

• Gluconeogenesis: For sustained glucose production, especially during prolonged fasting or severe hypoglycemia when glycogen stores are depleted, glucagon potently stimulates gluconeogenesis – the synthesis of glucose from non-carbohydrate precursors. PKA phosphorylation directly activates key gluconeogenic enzymes such as phosphoenolpyruvate carboxykinase (PEPCK) and fructose-1,6-bisphosphatase (FBPase), while simultaneously inhibiting glycolytic enzymes like pyruvate kinase and phosphofructokinase-1. This reciprocal regulation ensures that glucose production is favored over glucose utilization [Reference 6]. Precursors for gluconeogenesis include amino acids (e.g., alanine, glutamine) released from muscle protein breakdown, lactate from anaerobic glycolysis, and glycerol from triglyceride breakdown.

• Ketogenesis: Glucagon also promotes hepatic ketogenesis, the production of ketone bodies (beta-hydroxybutyrate and acetoacetate) from fatty acids. This process provides an alternative fuel source for peripheral tissues, particularly the brain, during periods of severe glucose deprivation, sparing glucose for critical functions.

2.3.2. Adipose Tissue

While the primary effects are hepatic, glucagon also stimulates lipolysis (breakdown of triglycerides into free fatty acids and glycerol) in adipose tissue. The released glycerol can then serve as a substrate for hepatic gluconeogenesis, further contributing to glucose production [Reference 7].

2.3.3. Kidney

Although to a lesser extent than the liver, the kidney also expresses GCGRs and can contribute to glucose production through gluconeogenesis, particularly during prolonged fasting. Glucagon plays a role in regulating this renal glucose output.

2.3.4. Pancreas (Paracrine Effects)

Glucagon also exerts paracrine effects within the islets themselves. It can stimulate somatostatin release from delta cells and, paradoxically, at very high concentrations, can inhibit insulin secretion from beta cells, although this effect is generally considered minor compared to its systemic actions [Reference 6].

2.4. Clinical Significance of Dysregulation

Dysregulation of glucagon secretion and action is implicated in several metabolic disorders. In type 2 diabetes mellitus, hyperglucagonemia (chronically elevated glucagon levels) is a common finding and contributes significantly to the persistent hyperglycemia seen in these patients, exacerbating hepatic glucose overproduction. This highlights glucagon as a potential therapeutic target in diabetes management. Conversely, impaired glucagon secretion or action can lead to recurrent or severe hypoglycemia, underscoring its vital protective role.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

3. Historical Development of Glucagon as a Therapeutic Agent

The journey of glucagon from a laboratory curiosity to a life-saving medication has been marked by significant scientific milestones and persistent challenges in pharmaceutical engineering.

3.1. Early Discoveries and Isolation

Following Kimball and Murlin’s initial observations in 1923, further efforts were directed towards isolating and purifying this ‘hyperglycemic factor’. The early 20th century saw numerous attempts to obtain purer extracts, driven by the desire to understand its chemical nature and physiological role. Eventually, in the 1950s, scientists like William W. Bromer, Arthur Staub, and Oscar K. Behrens at Eli Lilly and Company successfully isolated and crystallized glucagon from beef and pork pancreases, confirming its peptide nature and allowing for its amino acid sequencing [Reference 4]. This breakthrough was critical, enabling the production of more consistent and purer therapeutic preparations.

3.2. First Therapeutic Applications

With purified glucagon available, its therapeutic potential, particularly for severe hypoglycemic episodes in individuals with diabetes, became evident. Hypoglycemia, a common and dangerous complication of insulin therapy, can lead to confusion, seizures, coma, and even death if not promptly treated. Glucagon offered a rapid and effective means to raise blood glucose levels, especially when oral glucose administration was not feasible due as a result of unconsciousness or impaired swallowing.

Initial formulations, however, were rudimentary. They typically consisted of lyophilized (freeze-dried) powder in a vial, accompanied by a separate diluent (sterile water for injection). For administration, a caregiver had to manually reconstitute the powder by injecting the diluent into the powder vial, mixing it thoroughly, and then drawing the solution back into a syringe for injection. This multi-step process was cumbersome, time-consuming, and required a degree of dexterity and composure that might be difficult to maintain during an emergency, often leading to delays in treatment or errors in preparation.

3.3. Challenges with Early Formulations

Beyond the reconstitution burden, the inherent instability of glucagon in aqueous solution presented a significant hurdle for shelf-life and clinical utility. Glucagon, like many other peptides, is prone to physical degradation through self-association and fibril formation when dissolved in water, particularly under conditions of agitation, varying pH, or elevated temperature [Reference 3]. This aggregation leads to a loss of biological activity and the formation of visible particulates, rendering the product unsafe or ineffective. To circumvent this, manufacturers had to supply glucagon as a dry powder, limiting its readiness for immediate use and prolonging emergency response times.

3.4. Evolution Towards User-Friendliness

The recognition of these limitations spurred decades of research into developing more stable and convenient formulations. Early improvements included pre-filled syringes for the diluent, and later, auto-injector devices that simplified the reconstitution and injection steps. However, the fundamental problem of aqueous instability persisted, meaning glucagon still largely existed as a ‘kit’ requiring preparation.

Only in recent years have truly ready-to-use liquid formulations and needle-free options become available, marking a transformative shift in glucagon therapy. These advancements were driven by a deeper understanding of protein stability, the judicious selection of novel excipients, and the exploration of nonaqueous solvent systems, all underpinned by sophisticated material science principles.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

4. Challenges in Glucagon Formulation Stability and Shelf-Life

Glucagon’s instability in aqueous environments is a multifaceted challenge rooted in its physicochemical properties. Its propensity for both physical and chemical degradation pathways significantly compromises its therapeutic efficacy and limits its shelf-life in solution. Understanding these degradation mechanisms is crucial for designing stable formulations.

4.1. Physical Instability: Aggregation and Fibrillation

The predominant stability challenge for glucagon in aqueous solutions is its tendency to self-associate and form insoluble aggregates, particularly amyloid-like fibrils. This phenomenon, known as fibrillation, is a common issue for many therapeutic proteins and peptides.

4.1.1. Mechanism of Fibrillation

Fibrillation typically involves a series of steps:

1. Partial Unfolding: Under certain stress conditions (e.g., elevated temperature, extreme pH, agitation, presence of interfaces like air-liquid or liquid-solid), the native, thermodynamically stable conformation of glucagon can partially unfold, exposing hydrophobic regions that are normally buried within the protein’s core.
2. Self-Association/Nucleation: These exposed hydrophobic patches facilitate intermolecular interactions, leading to the formation of small, soluble oligomers. This is often the rate-limiting step.
3. Elongation: The oligomers act as templates, promoting further addition of unfolded or partially unfolded monomers, leading to the growth of protofilaments. These protofilaments then associate laterally to form larger, insoluble amyloid fibrils, characterized by a highly ordered cross-beta sheet structure [Reference 3].

4.1.2. Factors Influencing Fibrillation

Numerous factors can accelerate glucagon fibrillation:

• pH: Glucagon has an isoelectric point (pI) of approximately 7.5. At pH values close to its pI, the net charge on the molecule is minimal, reducing electrostatic repulsion between molecules and increasing their propensity to aggregate. Conversely, at pH values far from the pI, increased charge can help maintain solubility.
• Temperature: Elevated temperatures increase molecular kinetic energy, promoting unfolding and collisions, thus accelerating aggregation. Freeze-thaw cycles can also be detrimental due to ice formation and concentration effects.
• Concentration: Higher concentrations of glucagon increase the likelihood of intermolecular collisions, accelerating aggregation.
• Ionic Strength: High salt concentrations can screen electrostatic repulsions, facilitating hydrophobic interactions and aggregation.
• Agitation/Shear Stress: Mechanical agitation (e.g., shaking, stirring, pumping through narrow tubing) can induce unfolding at air-liquid interfaces, promoting aggregation. Similarly, interactions with surfaces (vials, stoppers, syringes) can act as nucleation sites.
• Time: Aggregation is generally a time-dependent process, with longer storage times increasing the risk.

4.1.3. Consequences of Fibrillation

Fibrillation leads to several undesirable outcomes:

• Loss of Biological Activity: Aggregated glucagon molecules lose their native structure and thus their ability to bind to the GCGR and elicit a physiological response, rendering the medication ineffective.
• Particulate Formation: Insoluble fibrils manifest as visible particles in the solution, which can raise safety concerns if injected, potentially leading to adverse reactions or blockage of injection devices.
• Immunogenicity: Aggregated proteins can be perceived as foreign by the immune system, potentially eliciting an immune response (antibody formation) that could neutralize the drug or cause other immunological reactions.

4.2. Chemical Instability

Beyond physical aggregation, glucagon is also susceptible to several chemical degradation pathways that can reduce its potency and alter its pharmacokinetic profile:

• Deamidation: This involves the hydrolysis of asparagine (Asn) and glutamine (Gln) residues, forming aspartic acid (Asp) and glutamic acid (Glu) respectively, and ammonia. Deamidation can lead to changes in charge, conformation, and ultimately, biological activity. Glucagon contains several Asn and Gln residues, making it susceptible to this pathway.
• Oxidation: Methionine (Met) and tryptophan (Trp) residues are particularly prone to oxidation, especially in the presence of oxygen, light, or metal ions. Oxidation of methionine to methionine sulfoxide can alter protein structure and function. Glucagon contains a methionine residue (Met-27), which is a common site of oxidative degradation [Reference 3].
• Disulfide Bond Scrambling/Cleavage: Although glucagon does not contain disulfide bonds, other peptides might. However, peptide bond hydrolysis (cleavage) can occur, particularly at susceptible sites, leading to fragmentation and loss of activity.

4.3. Traditional Solutions: Lyophilization

Historically, the most effective strategy to circumvent glucagon’s aqueous instability has been lyophilization (freeze-drying). This process involves freezing the aqueous solution and then subliming the ice under vacuum, effectively removing water while preserving the protein’s structure in a solid, amorphous or crystalline state. In the absence of bulk water, molecular mobility is severely restricted, dramatically slowing down both physical and chemical degradation processes, thereby extending shelf-life significantly [Reference 3].

However, lyophilization itself can be a stress on the protein, potentially leading to denaturation during freezing (cryo-stress) or drying (desiccation stress). To mitigate these effects, excipients are crucial components of lyophilized formulations.

4.4. Limitations of Lyophilization and the Need for Innovation

While effective for stability, lyophilized glucagon formulations impose significant practical limitations:

• Reconstitution Burden: As described earlier, the multi-step reconstitution process is cumbersome, time-consuming, and requires training, making it challenging for emergency use by untrained caregivers or in stressful situations.
• Risk of Error: Errors during reconstitution (e.g., incorrect diluent volume, incomplete mixing, improper handling) can lead to inaccurate dosing or degraded product.
• Patient Compliance: The complexity reduces patient and caregiver willingness to carry and use the product, potentially leading to delayed or omitted treatment of severe hypoglycemia.

These limitations have driven intensive research into innovative formulation strategies that can deliver glucagon in a stable, ready-to-use format, thereby improving patient outcomes and expanding its therapeutic utility.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

5. Formulations and Routes of Administration: A Material Science Perspective

The quest for stable, user-friendly glucagon formulations has led to significant advancements across various delivery mechanisms, each leveraging specific material science principles to overcome the inherent instability challenges. These innovations represent a paradigm shift from the traditional reconstitution model.

5.1. Lyophilized Glucagon for Injection (Traditional and Improved)

Despite the emergence of newer formulations, lyophilized glucagon kits remain a staple. However, even these have benefited from material science insights, particularly regarding the selection and function of excipients.

5.1.1. Role of Excipients

Excipients are pharmacologically inactive substances included in drug formulations to aid in stability, solubility, processability, and delivery. In lyophilized glucagon formulations, their primary roles are to:

• Cryoprotection: Protect the protein during the freezing stage by preventing ice crystal formation from damaging the protein structure and by forming an amorphous matrix that encases the protein. Common cryoprotectants include disaccharides like sucrose and trehalose. The ‘water replacement hypothesis’ suggests that these sugars can hydrogen bond directly with the protein surface, substituting for water molecules removed during drying and thus preserving the protein’s native conformation [Reference 3].
• Lyoprotection: Protect the protein during the drying stage (sublimation) and subsequent storage by maintaining its native structure in the dried state. Sugars also serve as lyoprotectants, forming a glassy, amorphous matrix that ‘freezes’ the protein in a stable conformation, severely restricting molecular mobility and thus inhibiting aggregation and chemical degradation.
• Bulking Agents: Add sufficient mass to the lyophilized cake for ease of handling and improved aesthetic appearance. Mannitol and glycine are common bulking agents, often forming crystalline structures that provide structural integrity to the dried cake.
• Buffers: Control the pH of the solution during reconstitution and storage to minimize chemical degradation pathways. Common buffers include sodium phosphate and sodium citrate.
• Surfactants: Reduce interfacial tension at air-liquid and liquid-solid interfaces, thereby minimizing protein adsorption to container surfaces and preventing aggregation induced by shear stress during processing. Polysorbates (e.g., Polysorbate 20 or 80) are frequently used [Reference 3].

By carefully optimizing the type and concentration of these excipients, manufacturers have been able to significantly enhance the stability of the dry powder, ensuring a longer shelf-life prior to reconstitution.

5.2. Nonaqueous Liquid Formulations (Ready-to-Use Injectable Glucagon)

The development of ready-to-use liquid glucagon formulations represents a significant leap forward in convenience and patient usability. The core innovation lies in circumventing the aqueous instability by formulating glucagon in nonaqueous or low-water activity solvent systems.

5.2.1. Solvent Systems and Stabilization Mechanism

Companies like Xeris Pharmaceuticals have pioneered such formulations (e.g., Gvoke HypoPen, Gvoke PFS). Their approach involves the use of specific nonaqueous solvents or solvent blends that act as effective protein stabilizers. Key examples include:

• Dimethyl Sulfoxide (DMSO): DMSO is a highly polar, aprotic solvent with a low dielectric constant. It is an excellent solvent for many peptides and proteins, including glucagon [Reference 2, 9]. Its low water activity and distinct molecular environment compared to water significantly reduce the propensity for glucagon to unfold and aggregate.
• N-methyl-2-pyrrolidone (NMP): Another polar aprotic solvent, NMP shares similar stabilizing properties to DMSO and can be used alone or in combination.
• Propylene Glycol (PG) and Glycerol: These are often used as cosolvents, providing further solvency and helping to fine-tune the physicochemical properties of the formulation. They can also contribute to stabilization by influencing protein hydration and solvent viscosity.
• Ethanol: In some formulations, small amounts of ethanol may be included as a cosolvent or to aid in solubility.

The underlying principle of stabilization in these nonaqueous systems is multifactorial. These solvents reduce the conformational flexibility of the protein, preventing the exposure of hydrophobic residues that drive aggregation. They also minimize water-mediated interactions, which are crucial for amyloid formation. By creating an environment with extremely low water activity, the chemical reactions dependent on water (e.g., deamidation) are also significantly slowed down [Reference 2, 9].

5.2.2. Advantages and Challenges

• Advantages: The primary benefit is the ready-to-use format, eliminating the need for reconstitution and thus significantly accelerating emergency response. This enhances patient safety and caregiver confidence. The formulation can be packaged in auto-injectors or pre-filled syringes, making administration simple and reliable.
• Material Compatibility Challenges: Nonaqueous solvents can present unique compatibility challenges with pharmaceutical packaging materials. Traditional elastomeric stoppers and plastic syringe barrels might leach extractables into the formulation or swell/degrade upon prolonged contact with these solvents. Therefore, specialized materials (e.g., fluoropolymer-coated stoppers, cyclic olefin polymer (COP) syringes) are often required to ensure product integrity and safety over the shelf-life [Reference 1].

5.3. Intranasal Glucagon (Needle-Free Delivery)

Intranasal glucagon represents another significant innovation, offering a completely needle-free alternative for emergency hypoglycemia treatment. This approach addresses the fear of needles and simplifies administration, making it more accessible to a wider range of users.

5.3.1. Formulation Strategy: Dry Powder Nasal Spray

The leading intranasal glucagon product, Baqsimi (Eli Lilly), employs a dry powder formulation rather than a liquid spray. This choice is critical for stability, as it avoids the inherent aqueous instability of glucagon. The formulation consists of glucagon co-spray-dried with excipients such as mannitol and sucrose [Reference 4].

• Particle Engineering: The physical properties of the powder, including particle size, morphology, and hygroscopicity, are meticulously engineered. The particles must be small enough to be aerosolized and delivered to the nasal mucosa but large enough to avoid significant deposition in the lungs. Controlling these properties is crucial for consistent dosing and effective absorption.
• Excipient Function: Mannitol and sucrose serve as bulking agents and cryoprotectants during the spray-drying process, ensuring glucagon stability in the solid state. They also contribute to the aerodynamic properties of the powder for efficient nasal delivery.

5.3.2. Delivery Device Design

The nasal spray device is integral to the product’s efficacy. It is designed to deliver a precise, consistent dose of the dry powder into the nasal cavity. Key design considerations include:

• Powder Reservoir: A sealed compartment to protect the dry powder from moisture and degradation until use.
• Actuation Mechanism: A simple, single-step activation button or plunger that releases the powder.
• Aerosol Generator: A mechanism to aerosolize the powder into a fine plume suitable for nasal inhalation, ensuring widespread distribution over the nasal mucosa.
• Humidity Protection: The device must protect the hygroscopic powder from ambient moisture before use.

5.3.3. Absorption Mechanism

Once delivered, the dry powder adheres to the nasal mucosa. The nasal cavity is highly vascularized with a large surface area and relatively permeable membrane, facilitating rapid absorption of the glucagon into the systemic circulation. Glucagon is absorbed directly into the bloodstream, bypassing first-pass metabolism in the liver to some extent, allowing for a rapid pharmacological effect [Reference 4]. The onset of action is comparable to injectable glucagon.

5.3.4. Advantages and Limitations

• Advantages: Needle-free administration is a significant psychological and practical advantage, especially for children and those with needle phobia. It simplifies the emergency procedure, making it accessible to untrained bystanders. The compact, ready-to-use device enhances patient compliance and readiness.
• Limitations: Nasal congestion, rhinitis, or other nasal conditions might impair absorption. While generally well-tolerated, some users may experience nasal irritation. The dry powder format requires careful device design to ensure consistent dose delivery.

5.4. Continuous Glucagon Delivery (Infusion Pumps/Artificial Pancreas Systems)

For advanced diabetes management, particularly in the context of artificial pancreas (closed-loop) systems, the ability to continuously infuse glucagon alongside insulin is highly desirable. This mimics the physiological dual-hormone control of the healthy pancreas more closely, allowing for proactive prevention and rapid correction of hypoglycemia, as well as tighter glycemic control.

5.4.1. Requirements for Infusion Formulations

Glucagon formulations for pump delivery face stringent stability requirements that are even more demanding than those for acute bolus injections:

• Long-Term Solution Stability: The formulation must remain stable in solution for several days (typically 2-7 days) at body temperature within the pump reservoir. This includes stability against aggregation and chemical degradation, even under constant agitation and exposure to pump components.
• High Concentration: To minimize infusion volumes and reservoir size, high glucagon concentrations are preferred.
• Material Compatibility: The formulation must be compatible with pump tubing, reservoirs, and other components, ensuring no leaching of extractables and no adsorption of glucagon to surfaces [Reference 2].
• Prevention of Fibrillation in Tubing: Glucagon’s tendency to fibrillate, particularly when exposed to shear stress or interfaces within narrow tubing, poses a significant challenge. Fibrillation can lead to blockages, inaccurate dosing, and loss of efficacy.

5.4.2. Formulation Strategies for Continuous Delivery

Research in this area has primarily focused on highly stabilized nonaqueous or specialized aqueous formulations:

• Nonaqueous Formulations: Similar to the ready-to-use injectable solutions, formulations based on DMSO, NMP, or other biocompatible nonaqueous solvents have shown promise for continuous infusion, due to their superior stability profile compared to aqueous solutions [Reference 2, 9]. These systems minimize water activity, thus preventing the primary drivers of glucagon aggregation and degradation.
• Highly Stabilized Aqueous Formulations (Experimental): While more challenging, some research has explored highly concentrated aqueous solutions incorporating specific combinations of excipients (e.g., highly soluble cyclodextrins, specific amino acids, or modified surfactants) that can prevent aggregation for extended periods. However, these are generally still in experimental or early clinical stages for pump use.

5.4.3. Role in Artificial Pancreas Systems

Bihormonal artificial pancreas systems aim to automate glucose management by continuously monitoring glucose levels and autonomously delivering both insulin (to lower glucose) and glucagon (to raise glucose) in response to real-time glucose fluctuations. Stable glucagon is indispensable for these systems, as it allows for:

• Hypoglycemia Prevention: Proactive delivery of micro-doses of glucagon can prevent or mitigate impending hypoglycemic events predicted by the algorithm, greatly enhancing safety and reducing patient burden.
• Post-Meal Glucose Control: Glucagon can also be used to mitigate post-prandial hyperglycemia, particularly in response to high-fat or high-protein meals that can cause delayed glucose excursions. By modulating hepatic glucose output, glucagon can help flatten glucose curves.
• Improved Glycemic Variability: The dual-hormone approach leads to tighter, more physiological glucose control with reduced glucose variability, an important long-term outcome for diabetes management [Reference 1].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

6. Potential Applications Beyond Diabetes Care

While glucagon’s primary therapeutic role has historically been limited to acute hypoglycemia reversal in diabetic patients, its multifaceted physiological actions suggest a broader spectrum of potential applications in various metabolic and non-metabolic disorders. The development of stable formulations is critical for enabling these expanded therapeutic uses.

6.1. Obesity and Metabolic Disorders

Glucagon plays a significant role in regulating energy expenditure and lipid metabolism, making it an attractive target for novel anti-obesity and metabolic disease treatments. However, glucagon alone is not typically used for chronic weight management due to side effects like transient nausea and its hyperglycemic effects.

6.1.1. Glucagon Receptor Agonists (GRAs)

Single glucagon receptor agonists (GRAs) have been investigated for their potential to increase energy expenditure, promote lipolysis, and improve lipid profiles. By stimulating the GCGR, GRAs can:

• Increase Energy Expenditure: Glucagon increases thermogenesis, particularly in the liver, leading to a modest increase in basal metabolic rate.
• Promote Lipolysis: It stimulates the breakdown of fat in adipose tissue, releasing free fatty acids and glycerol, which can then be used for energy or gluconeogenesis.
• Improve Lipid Profiles: Glucagon has been shown to reduce circulating triglycerides and VLDL-cholesterol, possibly by enhancing hepatic lipid oxidation or reducing hepatic lipid synthesis [Reference 7].

However, the hyperglycemic effect of standalone GRAs has limited their widespread use for obesity in non-diabetic individuals.

6.1.2. Multi-Agonist Therapies (GLP-1/GIP/Glucagon)

The most promising avenue for glucagon in obesity and diabetes treatment lies in its combination with other incretin hormones in dual or tri-agonist therapies. This poly-pharmacology approach aims to leverage the synergistic benefits of multiple metabolic pathways while mitigating potential side effects.

• Rationale: Glucagon’s energy expenditure and lipolytic effects can complement the glucose-lowering and appetite-suppressing effects of GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) receptor agonists. By combining these actions, a more comprehensive metabolic improvement can be achieved.

• Examples:

  • Dual Agonists (GLP-1/Glucagon): Compounds that activate both GLP-1 and glucagon receptors have demonstrated significant weight loss and improved glycemic control in clinical trials. The GLP-1 component counteracts glucagon’s hyperglycemic effect by stimulating insulin secretion and suppressing glucagon secretion, while the glucagon component enhances energy expenditure and promotes lipolysis, leading to greater weight loss than GLP-1 alone.
  • Tri-Agonists (GLP-1/GIP/Glucagon): The most advanced approach involves agonists that target GLP-1, GIP, and glucagon receptors. These compounds, such as retatrutide, have shown unprecedented levels of weight loss and improvements in glucose homeostasis in clinical studies. The synergistic activation of all three receptors appears to produce profound effects on satiety, glucose metabolism, lipid metabolism, and energy expenditure [Reference 7]. The GIP component further enhances insulin secretion and has its own metabolic benefits, while the GLP-1 and glucagon components contribute to appetite suppression and energy metabolism respectively.

• Non-alcoholic Steatohepatitis (NASH): Glucagon receptor agonism, particularly in multi-agonist constructs, is being explored for the treatment of NASH, a severe form of fatty liver disease. Glucagon’s ability to promote hepatic lipid oxidation and reduce hepatic fat accumulation makes it a promising therapeutic target for improving liver health in obese and diabetic patients.

6.2. Artificial Pancreas Systems (Detailed Role)

As elaborated previously, glucagon’s role in bi-hormonal artificial pancreas systems is crucial for achieving truly physiological glucose control. These systems aim to mimic the body’s natural glucose regulation by automatically adjusting insulin and glucagon delivery based on continuous glucose monitoring data. Stable, ready-to-use glucagon formulations are enabling the development and clinical deployment of these advanced devices, providing automated protection against hypoglycemia and enhancing glycemic stability, thus improving the quality of life for individuals with type 1 diabetes and potentially some with type 2 diabetes [Reference 1].

6.3. Other Potential Applications

• Cardiac Applications: Glucagon has been used historically as an inotropic agent in specific cardiac conditions, particularly in cases of beta-blocker overdose, due to its ability to increase heart rate and contractility independently of beta-adrenergic receptors. It activates adenylate cyclase directly, bypassing the blocked beta-receptors.
• Diagnostic Uses: Glucagon stimulation tests are employed in endocrinology to diagnose certain conditions, such as growth hormone deficiency or pheochromocytoma (a rare tumor of the adrenal gland).
• Gastrointestinal Applications: Glucagon can relax smooth muscle in the gastrointestinal tract, and has been used to facilitate diagnostic imaging procedures like endoscopy or radiology studies.

These diverse applications underscore glucagon’s pleiotropic effects and the ongoing efforts to harness its therapeutic potential beyond its established role in hypoglycemia management.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

7. Material Science Innovations in Glucagon Delivery Mechanisms

The transformation of glucagon from a challenging, unstable powder to stable, ready-to-use liquid and nasal spray forms is a testament to significant advancements in pharmaceutical material science. These innovations involve a sophisticated interplay of excipient selection, solvent engineering, and device design.

7.1. Precision Excipient Selection and Engineering

The judicious selection and engineering of excipients are paramount for glucagon formulation stability across all delivery platforms, particularly in lyophilized and dry powder nasal spray systems.

• Sugar-based Stabilizers (Sucrose, Trehalose): These disaccharides are classic examples of cryo- and lyoprotectants. Their amorphous nature in the dried state provides a rigid, glassy matrix that physically restricts the mobility of glucagon molecules, preventing aggregation. They also interact directly with the protein surface through hydrogen bonding, replacing water molecules and preserving the protein’s native conformation (water replacement hypothesis) [Reference 3]. For nasal sprays, they also contribute to the powder’s flow properties and aerosolization.
• Amino Acids (Glycine, Arginine): While sometimes used as bulking agents, certain amino acids like arginine can act as chaperones, preventing protein aggregation in solution by weakening protein-protein interactions. Glycine often serves as a bulking agent or tonicity modifier in lyophilized formulations.
• Surfactants (Polysorbates): Non-ionic surfactants like Polysorbate 20 and 80 are critical for minimizing protein adsorption to interfaces (air-liquid, protein-container) and preventing aggregation induced by mechanical stress (e.g., shaking during transport, or shear stress within infusion pumps). They achieve this by preferentially adsorbing to these interfaces, protecting the protein from denaturation [Reference 3].
• Buffers: Phosphate, citrate, and acetate buffers are carefully selected to maintain the optimal pH for glucagon stability, minimizing chemical degradation pathways like deamidation and oxidation.

7.2. Advanced Solvent and Cosolvent Systems

The development of nonaqueous liquid glucagon formulations hinges on the careful selection and optimization of solvent systems:

• Aprotic Polar Solvents (DMSO, NMP): These solvents are pivotal. Their ability to solubilize glucagon without promoting its aggregation is due to their distinct physicochemical properties: low water activity, high polarity, and aprotic nature. They modify the protein’s solvation shell and reduce the likelihood of unfavorable intermolecular interactions that lead to fibrillation [Reference 2, 9]. The selection is based on thorough compatibility studies with the drug substance and the intended container closure system.
• Polyols (Propylene Glycol, Glycerol): Often used as cosolvents, polyols can enhance solubility, modify viscosity, and contribute to the overall stability of the formulation. They can influence the dielectric constant of the solvent system, impacting protein-solvent interactions.
• Biocompatibility Considerations: While effective stabilizers, these solvents must also demonstrate adequate biocompatibility, low toxicity, and acceptable injection site tolerance, especially for ready-to-use formulations administered by patients. Extensive toxicological and clinical studies are required to confirm their safety profile.

7.3. Innovative Packaging and Device Engineering

The stability and usability of glucagon formulations are intrinsically linked to the materials used for packaging and the design of the delivery device.

• Advanced Container-Closure Systems: For nonaqueous liquid formulations, traditional glass vials and rubber stoppers can present challenges due to potential interactions with the solvents (e.g., leaching of extractables, sorption of drug, or degradation of stopper material). Manufacturers often resort to:
  • Coated Stoppers: Elastomeric stoppers with inert coatings (e.g., fluoropolymer films like Teflon) that act as a barrier, preventing direct contact between the formulation and the rubber, thus minimizing leaching and sorption.
  • Specialized Glass or Polymer Vials: Use of type I borosilicate glass with improved surface treatment or advanced polymer vials (e.g., cyclic olefin copolymer (COC) or cyclic olefin polymer (COP)) that offer superior chemical resistance and reduced protein adsorption compared to conventional plastics [Reference 1].
• Auto-injector and Pre-filled Syringe Design: These devices require precision engineering to ensure ease of use, accurate dosing, and protection of the fragile peptide. Components must be selected for chemical compatibility with the formulation over the product’s shelf-life. Springs, needles, and activation mechanisms must be robust and reliable for single-use emergency application.
• Nasal Device Engineering: For dry powder nasal sprays, the device is as critical as the formulation. It must reliably deliver a precise dose of powder with an optimal particle size distribution and plume geometry for effective nasal deposition and absorption [Reference 4]. This involves complex fluid dynamics and particle mechanics considerations, ensuring the powder remains dry and free-flowing until activation.
• Material Characterization Techniques: Advanced analytical techniques are crucial throughout the development process. These include:
  • Spectroscopic Methods (UV-Vis, Circular Dichroism (CD), Fourier-Transform Infrared (FTIR)): To monitor protein conformation and detect signs of unfolding or aggregation.
  • Light Scattering Techniques (Dynamic Light Scattering (DLS), Static Light Scattering (SLS)): To detect and characterize aggregates, measuring particle size and distribution.
  • Chromatography (SEC-HPLC): To separate and quantify monomers, oligomers, and fragments, assessing purity and aggregation.
  • Differential Scanning Calorimetry (DSC): To determine protein thermal stability and conformational transitions.
  • Rheology: To characterize the flow properties of liquid formulations, especially relevant for pump applications.
  • Microscopy (Electron Microscopy): To visualize amyloid fibrils and other particulate matter.

By integrating these material science innovations, researchers and pharmaceutical companies have successfully overcome long-standing challenges in glucagon formulation, ushering in an era of more accessible, reliable, and user-friendly glucagon therapies.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

8. Conclusion

Glucagon, the crucial counter-regulatory hormone to insulin, remains an indispensable therapeutic agent in the immediate management of severe hypoglycemia, a life-threatening complication for individuals with diabetes. The historical challenges associated with its inherent instability in aqueous solutions, primarily driven by its propensity to fibrillate and chemically degrade, long hindered its widespread and convenient use, necessitating cumbersome multi-step reconstitution processes in emergency scenarios.

The past two decades, however, have marked a transformative period in glucagon therapeutics, largely propelled by groundbreaking advancements in pharmaceutical material science and formulation technology. These innovations have systematically addressed and overcome the formidable stability barriers, leading to the development of a new generation of glucagon products. The advent of stable, ready-to-use nonaqueous liquid formulations, such as those delivered via auto-injectors or pre-filled syringes, has revolutionized emergency hypoglycemia treatment by eliminating the need for reconstitution, thereby ensuring rapid, confident, and simplified administration. Concurrently, the introduction of needle-free intranasal dry powder sprays has further enhanced patient and caregiver acceptance, providing an equally rapid and less intimidating option for glucagon delivery.

Beyond acute hypoglycemia, the enhanced stability of glucagon formulations has unlocked its potential for broader applications. Its pivotal role in the development of bi-hormonal artificial pancreas systems signifies a major step towards achieving more precise and automated glycemic control in diabetes, by proactively preventing hypoglycemia and optimizing post-meal glucose excursions. Furthermore, glucagon, particularly as a component of novel multi-agonist therapies (combining GLP-1, GIP, and glucagon receptor activation), is at the forefront of pharmaceutical research for the chronic management of obesity and related metabolic disorders like non-alcoholic steatohepatitis (NASH). These poly-pharmacology approaches leverage glucagon’s unique ability to enhance energy expenditure and promote lipolysis, offering unprecedented therapeutic efficacy in weight loss and metabolic improvement.

The successful translation of glucagon from a challenging protein to a versatile therapeutic is a compelling case study of how fundamental understanding of protein chemistry, meticulous excipient selection, sophisticated solvent engineering, and innovative device design can coalesce to significantly improve patient outcomes. Ongoing research continues to explore new chemical entities, delivery methods, and expanded indications for glucagon and its analogues, promising an even greater therapeutic impact in the evolving landscape of metabolic medicine. The journey of glucagon underscores the relentless pursuit of pharmaceutical scientists to overcome complex biophysical challenges, ultimately leading to more effective, safer, and user-friendly medications.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

References

1. Xeris Pharmaceuticals. (2019). Engineering biopharmaceutical formulations to improve diabetes management. Journal of Pharmaceutical Sciences, 108(1), 1-10. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC8004356/

2. Bachem, A., et al. (2014). Development of a highly stable, nonaqueous glucagon formulation for delivery via infusion pump systems. Journal of Pharmaceutical Sciences, 103(3), 755-763. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4495537/

3. Zhang, Y., et al. (2012). Effects of excipients on the chemical and physical stability of glucagon during freeze-drying and storage in dried formulations. International Journal of Pharmaceutics, 423(1), 1-8. Retrieved from https://pubmed.ncbi.nlm.nih.gov/22766900/

4. Glucagon (medication). (2025). In Wikipedia. Retrieved from https://en.wikipedia.org/wiki/Glucagon_%28medication%29

5. Glucagon. (2025). In Wikipedia. Retrieved from https://en.wikipedia.org/wiki/Glucagon

6. Glucagon Physiology. (2025). In Endotext. Retrieved from https://www.ncbi.nlm.nih.gov/sites/books/NBK279127/

7. Glucagon: A Key Regulator in Metabolic Homeostasis and Therapeutic Innovations. (2025). In International Journal of Medical and Clinical Research. Retrieved from https://www.iomcworld.com/open-access/glucagon-a-key-regulator-in-metabolic-homeostasis-and-therapeutic-innovations-133523.html

8. US20120046225A1 – Stable glucagon formulations for the treatment of hypoglycemia. (2012). Retrieved from https://patents.google.com/patent/US20120046225A1/en

9. Development of Stable Liquid Glucagon Formulations for Use in Artificial Pancreas. (2014). Journal of Pharmaceutical Sciences, 103(3), 764-772. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC4495524/

10. Glucagon Physiology. (2025). In StatPearls. Retrieved from https://www.ncbi.nlm.nih.gov/sites/books/NBK537082/